Skip to main content

Advertisement

Log in

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Serum albumin (SA) has been shown to be a prognostic marker in many hematological malignancies and in diffuse large B-cell lymphoma (DLBCL) prior to chemo-immunotherapy. SA may be a surrogate for age, comorbid status, and disease severity. Here, we aimed to assess whether SA can be an independent prognostic marker in patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP). Patients who presented at the Moffitt Cancer Center from 2007 to 2010 for DLBCL diagnosis or treatment were identified using our institutional database. Clinical and treatment data were recorded, including SA levels at diagnosis. Survival time was estimated using the Kaplan-Meier method, with Cox proportional hazard model used to identify potential risk factors for time-to-event data. From 295 identified patients, 171 were excluded for not having primary treatment at our institution or not having R-CHOP treatment. In 124 included patients (mean age at diagnosis of 58 years, 91 % Caucasian), 25 % were categorized as poor by the revised International Prognostic Index. Overall and progression-free survival at 4 years were 65 % (95 % CI 57–75) and 58 % (95 % CI 0.49–0.69), respectively. Using multivariate analysis, we found that the hazard index of death of patients with SA ≥3.7 g/dL was 26 % (95 % CI 13–53) of the hazard for those patients who had SA <3.7 g/dL when controlling for the revised International Prognostic Index risk and initial lymphocyte count. Our study shows that SA ≥3.7 g/dL is an independent prognostic marker in DLBCL patients treated with R-CHOP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cultrera JL, Dalia SM (2012) Diffuse large B-cell lymphoma: current strategies and future directions. Cancer Control 19(3):204–213

    PubMed  Google Scholar 

  2. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) N Engl J Med 329(14):987-994. doi:10.1056/nejm199309303291402

    Google Scholar 

  3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. doi:10.1056/NEJMoa011795

    Article  CAS  PubMed  Google Scholar 

  4. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferme C, Tilly H (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045. doi:10.1182/blood-2010-03-276246

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. doi:10.1182/blood-2006-08-038257

    Article  CAS  PubMed  Google Scholar 

  6. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12(5):460–468. doi:10.1016/s1470-2045(11)70069-9

    Article  CAS  PubMed  Google Scholar 

  7. Pavlidis AN, Kalef-Ezra J, Bourantas LC, Lambrou A, Mavridis A (1993) Serum tumor markers in non-Hodgkin’s lymphomas and chronic lymphocytic leukemia. Int J Biol Markers 8(1):14–20

    CAS  PubMed  Google Scholar 

  8. Suzumiya J, Ohshima K, Kanda M, Kato A, Shuuda K, Kimura N, Tamura K, Kikuchi M (1998) Intravascular large cell lymphoma associated with hypoalbuminemia. Leuk Lymphoma 32(1–2):179–182. doi:10.3109/10428199809059259

    CAS  PubMed  Google Scholar 

  9. Coiffier B, Lepage E (1993) Prognostic factors in large-cell lymphomas. Leuk Lymphoma 10(Suppl):57–60. doi:10.3109/10428199309149113

    Article  PubMed  Google Scholar 

  10. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Moller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trumper L, Siebert R, Loeffler M, Rosenwald A, Ott G (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263. doi:10.1182/blood-2012-06-435842

    Article  CAS  PubMed  Google Scholar 

  11. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkaer K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Moller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103–2113. doi:10.1038/leu.2012.83

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Sehn LH (2012) Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Prog 2012:402–409. doi:10.1182/asheducation-2012.1.402

    Google Scholar 

  13. Perry AM, Mitrovic Z, Chan WC (2012) Biological prognostic markers in diffuse large B-cell lymphoma. Cancer Control 19(3):214–226

    PubMed  Google Scholar 

  14. Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP, Loong EL, Sng I, Hwan-Cheong TL, Ang MK, Ngeow J, Tham CK, Tan MH, Lim ST (2008) Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 49(3):462–469. doi:10.1080/10428190701809156

    Article  CAS  PubMed  Google Scholar 

  15. Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. doi:10.1186/1475-2891-9-69

    Article  PubMed Central  PubMed  Google Scholar 

  16. Goldwasser P, Feldman J (1997) Association of serum albumin and mortality risk. J Clin Epidemiol 50(6):693–703

    Article  CAS  PubMed  Google Scholar 

  17. Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW (1996) Prolonged length of stay and reduced functional improvement rate in malnourished stroke rehabilitation patients. Arch Phys Med Rehabil 77(4):340–345

    Article  CAS  PubMed  Google Scholar 

  18. Murray MJ, Marsh HM, Wochos DN, Moxness KE, Offord KP, Callaway CW (1988) Nutritional assessment of intensive-care unit patients. Mayo Clin Proc 63(11):1106–1115

    Article  CAS  PubMed  Google Scholar 

  19. Chihara D, Oki Y, Ine S, Yamamoto K, Kato H, Taji H, Kagami Y, Yatabe Y, Nakamura S, Morishima Y (2009) Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leuk Lymphoma 50(12):1999–2004. doi:10.3109/10428190903318311

    Article  CAS  PubMed  Google Scholar 

  20. Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M (2010) Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 51(5):813–821. doi:10.3109/10428191003721359

    Article  CAS  PubMed  Google Scholar 

  21. Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ, Lin TY, Huang HQ, Li ZM (2011) Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. Int J Hematol 94(2):178–184. doi:10.1007/s12185-011-0898-4

    Article  PubMed  Google Scholar 

  22. Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339(21):1506–1514. doi:10.1056/nejm199811193392104

    Article  CAS  PubMed  Google Scholar 

  23. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E, Integruppo Italiano L (2006) Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107(12):4643–4649. doi:10.1182/blood-2005-11-4659

    Article  CAS  PubMed  Google Scholar 

  24. Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, Janssen W, List AF, Anasetti C (2011) Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 17(3):384–393. doi:10.1016/j.bbmt.2010.07.011

    Article  PubMed  Google Scholar 

  25. Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF (2012) Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. Am J Hematol 87(11):1006–1009. doi:10.1002/ajh.23303

    Article  CAS  PubMed  Google Scholar 

  26. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/jco.2006.09.2403

    Article  PubMed  Google Scholar 

  27. Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239–241

    Article  Google Scholar 

  28. Perry AM, Cardesa-Salzmann TM, Meyer PN, Colomo L, Smith LM, Fu K, Greiner TC, Delabie J, Gascoyne RD, Rimsza L, Jaffe ES, Ott G, Rosenwald A, Braziel RM, Tubbs R, Cook JR, Staudt LM, Connors JM, Sehn LH, Vose JM, Lopez-Guillermo A, Campo E, Chan WC, Weisenburger DD (2012) A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood 120(11):2290–2296. doi:10.1182/blood-2012-05-430389

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E (2011) Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 117(26):7070–7078. doi:10.1182/blood-2011-04-345256

    Article  PubMed  Google Scholar 

  30. Mackintosh JF, Cowan RA, Jones M, Harris M, Deakin DP, Crowther D (1988) Prognostic factors in stage I and II high and intermediate grade non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 24(10):1617–1622

    Article  CAS  PubMed  Google Scholar 

  31. Lin TL, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, Tang TC, Chang H, Hung YS (2012) The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol 91(9):1383–1391. doi:10.1007/s00277-012-1463-9

    Article  PubMed  Google Scholar 

  32. Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK (2012) B cell non-Hodgkin’s lymphoma: experience from a tertiary care cancer center. Ann Hematol 91(10):1603–1611. doi:10.1007/s00277-012-1491-5

    Article  CAS  PubMed  Google Scholar 

  33. Steward WP, Todd ID, Harris M, Jones JM, Blackledge G, Wagstaff J, Anderson H, Wilkinson PM, Crowther D (1984) A multivariate analysis of factors affecting survival in patients with high-grade histology non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 20(7):881–889

    Article  CAS  PubMed  Google Scholar 

  34. Khera R, Jain S, Kumar L, Thulkar S, Vijayraghwan M, Dawar R (2010) Diffuse large B-cell lymphoma: experience from a tertiary care center in North India. Med Oncol 27(2):310–318. doi:10.1007/s12032-009-9211-2

    Article  PubMed  Google Scholar 

  35. Hennig B, Honchel R, Goldblum SE, McClain CJ (1988) Tumor necrosis factor-mediated hypoalbuminemia in rabbits. J Nutr 118(12):1586–1590

    CAS  PubMed  Google Scholar 

  36. Brenner DA, Buck M, Feitelberg SP, Chojkier M (1990) Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest 85(1):248–255. doi:10.1172/jci114419

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213. doi:10.1207/S15327914nc392_8

    Article  CAS  PubMed  Google Scholar 

  38. Ballmer PE, Ochsenbein AF, Schutz-Hofmann S (1994) Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 43(6):697–705

    Article  CAS  PubMed  Google Scholar 

  39. Aviles A, Yanez J, Lopez T, Garcia EL, Guzman R, Diaz-Maqueo JC (1995) Malnutrition as an adverse prognostic factor in patients with diffuse large cell lymphoma. Arch Med Res 26(1):31–34

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Rasa Hamilton (Moffitt Cancer Center) for editorial assistance.

Conflict of interest

No authors have any conflicts of interest to report.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Samir Dalia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dalia, S., Chavez, J., Little, B. et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann Hematol 93, 1305–1312 (2014). https://doi.org/10.1007/s00277-014-2031-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2031-2

Keywords

Navigation